Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Repare Therapeutics Inc. (RPTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/13/2023 8-K Quarterly results
10/06/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types, genomic alterations, PARPi choice or platinum resistance Roche has included a camonsertib-based arm in its Phase 2 TAPISTRY study and its Phase 1/2 Morpheus Lung study of multiple combinations in metastatic non-small cell lung cancer Reported clinical proof of concept for lunresertib in June 2023 including achievement of monotherapy safety and tolerability primary endpoints and identification of two proposed dose/schedules Presented early lunresertib combination response data in June 2023, and expects to present further Phase 1 MYTHIC Module 2 data at a m..."
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Repare Therapeutics Reports Proof of Concept for Lunresertib in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials"
06/06/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting Camonsertib combination therapy showed 48% CBR across tumor types regardless of choice of PARP inhibitor or platinum resistance, with a favorable safety and tolerability profile Company on track to report initial RP-6306 monotherapy data from Phase 1 MYTHIC clinical trial in June 2023 Announced the appointment of Susan Molineaux, Ph.D., and departure of Jerel Davis, Ph.D. on our Board of Directors, as well as the addition of Daniel Belanger to the senior leadership team CAMBRIDGE, Mass. & MONTREAL —May 9, 2023"
04/28/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors"
04/18/2023 8-K Quarterly results
03/10/2023 8-K Other Events  Interactive Data
03/01/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 8-K Quarterly results
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A ARK Investment Management LLC reports a 5.8% stake in Repare Therapeutics Inc.
02/09/2023 SC 13G/A FMR LLC reports a 2.1% stake in REPARE THERAPEUTICS INC
01/06/2023 SC 13D/A Versant Venture Capital V, L.P. reports a 5% stake in REPARE THERAPEUTICS INC.
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
08/04/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
06/13/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
06/06/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
06/01/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
04/26/2022 EFFECT Form EFFECT - Notice of Effectiveness:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy